TP53 and medulloblastoma: Taken together, these experiments show that p53 protects against drug-induced cell death in medulloblastoma cells and its genetic- or chemical-suppression results in a significant increase in cell sensitivity to VMY and doxorubicin, an experimental and a clinical drug, respectively.